These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18618289)

  • 21. Mucopolysaccharidosis type II, Hunter's syndrome.
    Tylki-Szymańska A
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():107-13. PubMed ID: 25345092
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment.
    D'Avanzo F; Rigon L; Zanetti A; Tomanin R
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32070051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hearing loss and airway problems in children with mucopolysaccharidoses].
    Santos S; López L; González L; Domínguez MJ
    Acta Otorrinolaringol Esp; 2011; 62(6):411-7. PubMed ID: 21757178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome).
    Martin R; Beck M; Eng C; Giugliani R; Harmatz P; Muñoz V; Muenzer J
    Pediatrics; 2008 Feb; 121(2):e377-86. PubMed ID: 18245410
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idursulfase in Hunter syndrome treatment.
    Zareba G
    Drugs Today (Barc); 2007 Nov; 43(11):759-67. PubMed ID: 18174963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene Therapy for Mucopolysaccharidosis Type II-A Review of the Current Possibilities.
    Zapolnik P; Pyrkosz A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical assessment of upper airway and its complications in Hunter syndrome.
    Iijima M; Hirano D; Yokoi K; Kobayashi H; Fujiwara M; Ida H; Oishi K
    Pediatr Int; 2021 May; 63(5):543-549. PubMed ID: 32935418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls.
    Burton BK; Giugliani R
    Eur J Pediatr; 2012 Apr; 171(4):631-9. PubMed ID: 22383073
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2014 Jan; (1):CD008185. PubMed ID: 24399699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008185. PubMed ID: 22071845
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome).
    da Silva EM; Strufaldi MW; Andriolo RB; Silva LA
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD008185. PubMed ID: 26845288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mucopolysaccharidosis type II in females and response to enzyme replacement therapy.
    Jurecka A; Krumina Z; Żuber Z; Różdżyńska-Świątkowska A; Kłoska A; Czartoryska B; Tylki-Szymańska A
    Am J Med Genet A; 2012 Feb; 158A(2):450-4. PubMed ID: 22246721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of the behavioural manifestations of Hunter syndrome.
    Roberts J; Stewart C; Kearney S
    Br J Nurs; 2016 Jan 14-27; 25(1):22, 24, 26-30. PubMed ID: 26768041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II.
    Higuchi T; Shimizu H; Fukuda T; Kawagoe S; Matsumoto J; Shimada Y; Kobayashi H; Ida H; Ohashi T; Morimoto H; Hirato T; Nishino K; Eto Y
    Mol Genet Metab; 2012 Sep; 107(1-2):122-8. PubMed ID: 22704483
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of Fluid Biomarkers Reveals Lysosome Dysfunction and Neurodegeneration in Neuronopathic MPS II Patients.
    Bhalla A; Ravi R; Fang M; Arguello A; Davis SS; Chiu CL; Blumenfeld JR; Nguyen HN; Earr TK; Wang J; Astarita G; Zhu Y; Fiore D; Scearce-Levie K; Diaz D; Cahan H; Troyer MD; Harris JM; Escolar ML
    Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.
    Muenzer J; Lamsa JC; Garcia A; Dacosta J; Garcia J; Treco DA
    Acta Paediatr Suppl; 2002; 91(439):98-9. PubMed ID: 12572850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis and management of respiratory involvement in Hunter syndrome.
    Kamin W
    Acta Paediatr; 2008 Apr; 97(457):57-60. PubMed ID: 18339190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome).
    Peters C; Krivit W
    Bone Marrow Transplant; 2000 May; 25(10):1097-9. PubMed ID: 10828872
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.